JOP20200296A1 - عمليات صنع وأشكال بلورية من mdm2 مثبط - Google Patents

عمليات صنع وأشكال بلورية من mdm2 مثبط

Info

Publication number
JOP20200296A1
JOP20200296A1 JOP/2020/0296A JOP20200296A JOP20200296A1 JO P20200296 A1 JOP20200296 A1 JO P20200296A1 JO P20200296 A JOP20200296 A JO P20200296A JO P20200296 A1 JOP20200296 A1 JO P20200296A1
Authority
JO
Jordan
Prior art keywords
making
processes
crystalline forms
mdm2 inhibitor
intermediates
Prior art date
Application number
JOP/2020/0296A
Other languages
English (en)
Inventor
M Fox Brian
R Mcgee Lawrence
Cochran Brian
S Lucas Brian
Wortman Sarah
Caille Sebastien
Vounatsos Filisaty
Wiedemann Sean
Fang Yuanqing
Bio Matthew
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20200296A1 publication Critical patent/JOP20200296A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

يتعلق الاختراع الحالي بعمليات لصناعة 2-((3R، 5R، 6S)-5-(3-كلوروفينيل)-6-(4-كلوروفينيل)-1-((S)-1-(أيزوبروبيل سلفونيل)-3-ميثيل بيوتان-2-يل)-3-ميثيل-2-أوكسوببريدين -3-يل) حمض الأسيتيك ومركبات وسيطة وعمليات لصناعة المركبات الوسيطة. كما يقدم الاختراع أيضا الصيغ البلورية للمركب والمركبات الوسيطة.
JOP/2020/0296A 2013-06-10 2013-06-10 عمليات صنع وأشكال بلورية من mdm2 مثبط JOP20200296A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10

Publications (1)

Publication Number Publication Date
JOP20200296A1 true JOP20200296A1 (ar) 2017-06-16

Family

ID=51063849

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0296A JOP20200296A1 (ar) 2013-06-10 2013-06-10 عمليات صنع وأشكال بلورية من mdm2 مثبط
JOP/2014/0186A JO3768B1 (ar) 2013-06-10 2014-06-10 عمليات صنع وأشكال بلورية من مثبط mdm2

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2014/0186A JO3768B1 (ar) 2013-06-10 2014-06-10 عمليات صنع وأشكال بلورية من مثبط mdm2

Country Status (37)

Country Link
US (10) US9376386B2 (ar)
EP (2) EP3008039B1 (ar)
JP (4) JP6998655B2 (ar)
KR (3) KR20210121270A (ar)
CN (3) CN110003092A (ar)
AP (1) AP2015008891A0 (ar)
AR (2) AR096582A1 (ar)
AU (4) AU2014278428B2 (ar)
BR (2) BR112015031004B1 (ar)
CA (4) CA3115609C (ar)
CL (3) CL2015003589A1 (ar)
CR (2) CR20210290A (ar)
CY (1) CY1123661T1 (ar)
DK (1) DK3008039T3 (ar)
EA (3) EA201891642A1 (ar)
ES (1) ES2851023T3 (ar)
HR (1) HRP20202065T1 (ar)
HU (1) HUE053047T2 (ar)
IL (4) IL297860A (ar)
JO (2) JOP20200296A1 (ar)
LT (1) LT3008039T (ar)
MA (3) MA38714A1 (ar)
MX (2) MX2015016856A (ar)
MY (1) MY194848A (ar)
NZ (1) NZ714821A (ar)
PE (2) PE20210153A1 (ar)
PH (1) PH12015502705B1 (ar)
PL (1) PL3008039T3 (ar)
PT (1) PT3008039T (ar)
RS (1) RS61192B1 (ar)
SG (2) SG11201509896VA (ar)
SI (1) SI3008039T1 (ar)
TN (1) TN2015000521A1 (ar)
TW (3) TWI791153B (ar)
UA (1) UA121301C2 (ar)
UY (1) UY35605A (ar)
WO (1) WO2014200937A1 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX2020013670A (es) 2013-11-11 2022-09-30 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
KR20210019422A (ko) * 2018-04-30 2021-02-22 카토스 테라퓨틱스, 인크. 암 치료 방법
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
JP7408635B2 (ja) * 2018-08-31 2024-01-05 アムジエン・インコーポレーテツド Ｍｄｍ２阻害剤を調製する方法
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
EP4204812A2 (en) 2020-08-27 2023-07-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CA3227793A1 (en) * 2021-08-05 2023-02-09 Yong Moon Choi Phenyl carbamate crystalline form and method for preparing same
WO2023039161A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating cancer dependent on myc gene expresssion
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
KR100483222B1 (ko) 1994-08-19 2005-04-15 아보트 러보러터리즈 엔도텔린 길항제
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
BR9815296A (pt) 1997-08-04 2001-11-20 Abbott Lab Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina
WO1999031507A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
US7229500B2 (en) * 2000-11-20 2007-06-12 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
AU2002305450A1 (en) 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
ATE389400T1 (de) 2001-12-18 2008-04-15 Hoffmann La Roche Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
ES2314660T3 (es) 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag Nuevas cis-imidazolinas.
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
CA2583217C (en) 2004-10-18 2011-05-31 Amgen Inc. 1,3,4-thiadiazole compounds as protein kinase inhibitors
CN102372705A (zh) 2005-02-18 2012-03-14 田边三菱制药株式会社 脯氨酸衍生物的盐，其溶剂合物，及其生产方法
AU2006224765B2 (en) 2005-03-16 2012-02-09 F.Hoffmann-La Roche Ag CIS-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
AU2006232517A1 (en) 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
EP1888120B1 (en) 2005-06-07 2012-12-05 Ramot at Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007015929A2 (en) 2005-07-27 2007-02-08 University Of Toledo Epothilone analogues
EP2130822A1 (en) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
US20100092427A1 (en) 2006-07-19 2010-04-15 The University Of Georgia Research Foundation Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy
WO2008021339A2 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as pr modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2681136C (en) 2007-03-23 2012-05-22 Amgen Inc. Heterocyclic compounds and their uses
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
CA2680853C (en) 2007-03-23 2012-07-17 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
EP2183232B1 (en) 2007-08-02 2013-03-06 Amgen, Inc Pi3 kinase modulators and methods of use
BRPI0817850A2 (pt) 2007-10-09 2015-04-07 Hoffmann La Rouche Ag F Cis-imidazolinas quirais
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
WO2009082038A2 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
EP2268616A1 (en) 2008-03-21 2011-01-05 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
EP2387570A1 (en) 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
AU2010216239B2 (en) 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US20120190666A1 (en) 2009-05-13 2012-07-26 Amgen Inc. Heteroaryl Compounds as PIKK Inhibitors
UY32743A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2765819A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of pi3 k activity
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
BR112012000660A2 (pt) 2009-06-25 2016-11-16 Amgen Inc compostos heterociclos e seus usos
IN2012DN01693A (ar) 2009-08-26 2015-06-05 Novartis Ag
EP2486044A2 (en) 2009-10-09 2012-08-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011100434A2 (en) * 2010-02-10 2011-08-18 Chistopher Su-Yan Own Aberration-correcting dark-field electron microscopy
IT1399923B1 (it) 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
KR101921102B1 (ko) * 2011-04-28 2018-11-22 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 아조디카본아미드의 신규 제조법
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
US20160002185A1 (en) 2013-02-19 2016-01-07 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
US20140364455A1 (en) 2014-12-11
TWI698428B (zh) 2020-07-11
SG10201801402XA (en) 2018-04-27
JP6891322B2 (ja) 2021-06-18
MX2015016856A (es) 2016-04-07
IL242622A0 (en) 2016-02-01
US9376386B2 (en) 2016-06-28
CA3201958A1 (en) 2014-12-18
IL242622B (en) 2019-06-30
US20200281912A1 (en) 2020-09-10
JP2020147573A (ja) 2020-09-17
MA53572A1 (fr) 2021-10-29
HRP20202065T1 (hr) 2021-02-19
BR112015031004A2 (pt) 2020-05-12
TWI649306B (zh) 2019-02-01
ES2851023T3 (es) 2021-09-02
JP2021130685A (ja) 2021-09-09
IL281807A (en) 2021-05-31
AU2014278428B2 (en) 2018-11-15
BR122020003153B1 (pt) 2022-09-27
HUE053047T2 (hu) 2021-06-28
US9757367B2 (en) 2017-09-12
US9623018B2 (en) 2017-04-18
MA43288B1 (fr) 2020-10-28
NZ753956A (en) 2020-12-18
EP3805232A1 (en) 2021-04-14
PE20210153A1 (es) 2021-01-26
SI3008039T1 (sl) 2021-03-31
AR096582A1 (es) 2016-01-20
EP3008039B1 (en) 2020-11-11
AU2020267169A1 (en) 2020-12-03
CA3115609A1 (en) 2014-12-18
IL266504B (en) 2021-04-29
PH12015502705A1 (en) 2016-03-14
PE20160113A1 (es) 2016-03-03
CA2914723A1 (en) 2014-12-18
JP2016528179A (ja) 2016-09-15
CA2914723C (en) 2021-06-15
JP7263439B2 (ja) 2023-04-24
WO2014200937A1 (en) 2014-12-18
US9855259B2 (en) 2018-01-02
IL281807B (en) 2022-12-01
TWI791153B (zh) 2023-02-01
EA202091612A1 (ru) 2020-10-05
CN110627708A (zh) 2019-12-31
JP2023089126A (ja) 2023-06-27
SG11201509896VA (en) 2016-01-28
IL281807B2 (en) 2023-04-01
NZ714821A (en) 2020-10-30
AU2022271425A1 (en) 2022-12-22
KR20210121270A (ko) 2021-10-07
BR112015031004B1 (pt) 2022-09-20
TN2015000521A1 (en) 2017-04-06
EP3008039A1 (en) 2016-04-20
US20160289190A1 (en) 2016-10-06
EA031254B1 (ru) 2018-12-28
AU2018260844B2 (en) 2020-08-13
KR20230019216A (ko) 2023-02-07
US20160287570A1 (en) 2016-10-06
CA3200532A1 (en) 2014-12-18
UY35605A (es) 2015-01-30
CN105358530A (zh) 2016-02-24
DK3008039T3 (da) 2021-01-04
IL266504A (en) 2019-07-31
CR20210290A (es) 2021-07-23
JO3768B1 (ar) 2021-01-31
TW201922705A (zh) 2019-06-16
UA121301C2 (uk) 2020-05-12
MY194848A (en) 2022-12-19
US20160289243A1 (en) 2016-10-06
CN110003092A (zh) 2019-07-12
PH12015502705B1 (en) 2016-03-14
CR20160010A (es) 2016-02-04
CL2019000056A1 (es) 2019-05-03
US20160289178A1 (en) 2016-10-06
MA43288A1 (fr) 2020-04-30
PT3008039T (pt) 2021-01-13
EA201891642A1 (ru) 2019-08-30
US20220280496A1 (en) 2022-09-08
AU2018260844A1 (en) 2018-11-22
MA38714A1 (fr) 2017-10-31
JP6998655B2 (ja) 2022-02-04
IL297860A (en) 2023-01-01
AU2014278428A1 (en) 2015-11-26
EA201592305A1 (ru) 2016-05-31
US9801867B2 (en) 2017-10-31
MX2019012007A (es) 2019-11-11
CY1123661T1 (el) 2022-03-24
TW202035370A (zh) 2020-10-01
PL3008039T3 (pl) 2021-04-19
LT3008039T (lt) 2021-01-25
CL2015003589A1 (es) 2016-06-17
AU2020267169B2 (en) 2022-08-25
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
US20160264526A1 (en) 2016-09-15
CA3115609C (en) 2023-08-08
AP2015008891A0 (en) 2015-11-30
US20230301974A1 (en) 2023-09-28
AR119727A2 (es) 2022-01-05
KR20160018576A (ko) 2016-02-17
US20180092898A1 (en) 2018-04-05
CL2021000566A1 (es) 2021-09-03

Similar Documents

Publication Publication Date Title
PH12015502705B1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
SG10201903532XA (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
AR098929A1 (es) Formas sólidas cristalinas del compuesto 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforilamino)propanoato
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
AR124856A2 (es) Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
AU2015292632B2 (en) Aldosterone synthase inhibitors
HK1206337A1 (en) Crystalline forms of (s)-4-aminon-(1-(4-chlorophenyl)-3- hydroxypropyl)-1-(7h -pyrrolo[2, 3-d]pyrimidi n-4-yl) piperidine-4- carboxamide (s)-4--n-(1-(4-)-3-)-1-(7h-[23-d]-4-) -4-
GB201114389D0 (en) Novel compounds
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
EA202190632A1 (ru) Способы получения ингибитора mdm2
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR
IN2013MU02719A (ar)
MX2014002343A (es) Inhibidores de parp.